Xing-sheng Hu
Beijing Key Laboratory Of Clinical Study On Anticancer Molecular Targeted Drugs, Chinese Academy Of Medical Sciences & Peking Union Medical College
Beijing, 100021, China
Beijing, 100021, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Neurokinin-1 receptor antagonists in the current management of chemotherapy-induced nausea and vomiting.
Journal: Frontiers of medicine
Published: October 21, 2024
Dacomitinib for Advanced Non-small Cell Lung Cancer Patients Harboring Major Uncommon EGFR Alterations: A Dual-Center, Single-Arm, Ambispective Cohort Study in China.
Journal: Frontiers in pharmacology
Published: April 13, 2022
Efficacy of dacomitinib in patients with non-small cell lung cancer carrying complex EGFR mutations: a real-world study.
Journal: Journal of thoracic disease
Published: November 22, 2021
Immune checkpoint inhibitors combined with angiogenic inhibitors in the treatment of locally advanced or metastatic lung adenocarcinoma patients.
Journal: Cancer immunology, immunotherapy : CII
Published: September 13, 2021
Circulating tumor cells (CTCs)/circulating tumor endothelial cells (CTECs) and their subtypes in small cell lung cancer: Predictors for response and prognosis.
Journal: Thoracic cancer
Published: July 08, 2021
Rechallenge pemetrexed-based chemotherapy provides an option for initially benefited patients with advanced lung adenocarcinoma.
Journal: Chinese medical journal
Published: June 16, 2021
Survival and pretreatment prognostic factors for extensive-stage small cell lung cancer: A comprehensive analysis of 358 patients.
Journal: Thoracic cancer
Published: March 13, 2021
Emerging immunotherapy targets in lung cancer.
Journal: Chinese medical journal
Published: September 18, 2020
CD56+ lymphoepithelioma-like carcinoma of the lung: A case report and literature review.
Journal: World journal of clinical cases
Published: December 25, 2019
Circular RNA profiling identified as a biomarker for predicting the efficacy of Gefitinib therapy for non-small cell lung cancer.
Journal: Journal of thoracic disease
Published: July 10, 2019
Evidence of NTRK1 Fusion as Resistance Mechanism to EGFR TKI in EGFR+ NSCLC: Results From a Large-Scale Survey of NTRK1 Fusions in Chinese Patients With Lung Cancer.
Journal: Clinical lung cancer
Published: June 11, 2019
Last Updated: 09/26/2026